1Vannucchi MG.Receptors in intestinal cells of cajal:identification and possible physiological roles[J].Micros Res Tech,1999,47(5):325-335.
2Tsujimura K,Hashimoto K,Kitayma H,et al.Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site[J].Blood,1999,93 (4):1319 -1329.
3Tonary AM,Macdonald EA,Faught W,et al.Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis[J].Int J Cancer,2000,89(3):242-250.
4Arber D A,Tamayo R,Weiss LM.Paraffin section detection of the c-kit gene product(CD117) in human tissues:value in the diagnosis of mast cell disorders[J].Hum Pathol,1998,29(5):498-504.
6Versnel MA,Haarbrink M,Langerak AW,et al.Human ovarian tumors of epithelial origin express PDGF in vitro and in vivo[J].Cancer Genet Cytogenet,1994,73(1):60-64.
7Henriksen R,Funa K,Wilander E,et al.Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms[J].Cancer Res,1993,53(19):4550-4554.
10Sjoblom T,Shimazu A,O' Brien KP,et al.Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis[J].Cancer Res,2001,61 (15):5778-5783.
2Mah Becherd MCM , Ceraline J , Deplaneque G , et al . Anti-angiogenic effects of the thienopyridine SR 25989 in vitro and in vivo in a murine pulmonary metastasis model[J]. Br J Cancer , 2002 ,86(5)803-810.
3Kawai T , Hiroi S , Torikata C . The activity and expression of thymidine phoisphorylase in human solid tumours[J]. Eur J Cancer, 1996,32A(7): 1227-1232.
4Kawai T,Hiroi S, Torikata C.Expression in lung carcinoma of platelet-derived growth factor and it receptors l[J]. Lab Invest, 1997,77(5): 431-436.
5Heldin NE, Usuki K, Bergh J, et al. Differential expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human lung carcinoma cell lines[J].Br J Cancer, 1993, 68(4):708-711.
6Giatromanolaki A, Koukourakis MI, Comley M, et al. Platelet derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer l[J]. J Pathol, 1997,181(2):196-199.
7Koukourakis MI, Giatromanolaki A, O'Byrne KJ, et al. Platelet derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non small cell lung cancer[J]. Br J Cancer, 1997, 75(4);477-481.
8Yano T, Takeo S. Thymidine phosphorylase activity in non small cell lung carcinoma tissues[J]. Cancer , 2001,92(10):2658-2661.
9Shou Y, Hirano T, Gong Y, et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer[J]. Br J Cancer, 2001, 85(11):1706-1712.
6Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin[J]. J Clin Oncol, 1991,9(3) :389-393.
7Taniguchi M, Nishida T, Hirota S, et al. Effect of C-Kit mutation on prognosis of gastrointestinal stromal tumors [J]. Cancer Res,1999,59(17) : 4297-4300.
8Komdeur R, Hoekstra HJ, Molenaar WM, et al. Clinicopath ologic assessment of postradiation sarcomas: KIT as a potential treatment target [J].Clin Cancer Res, 2003,9 (8) :2926- 2932.
9Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of C-Kit and stem cell factor[J]. Cancer Res, 1996,56(2): 370-376.
10Santin AD, Fenghuang Z, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium dentification of candidate molecular markers for ovarian cancer diagnosis and therapy[J]. Cancer, 2004,11 (2) : 14-25.
